PF 06273588

Drug Profile

PF 06273588

Alternative Names: PF-06273588

Latest Information Update: 25 Feb 2014

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 25 Feb 2014 Discontinued - Phase-I for HIV infections (in volunteers) in United Kingdom (IV)
  • 25 Feb 2014 Discontinued - Phase-I for HIV infections (in volunteers) in United Kingdom (PO)
  • 01 Jul 2011 Phase-I clinical trials in HIV infections in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top